295 Non-Hodgkin Lymphoma in children: single center experience during 20 years

Lymphomas are the third most common malignant disease in childhood, after leukemia and brain tumors. The aim of this study is to show stratification by gender and age as well as long term survival in pediatric patients diagnosed with Non-Hodgkin Lymphoma in our center.Our retrospective analysis incl...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2021-10, Vol.106 (Suppl 2), p.A125-A125
Main Authors: Bilić, Ernest, Šalek, Zrinko, Jelić, Matej, Turudić, Daniel, Ivančić, Petra, Pavlović, Maja, Femenić, Ranka, Petrović-Gluščić, Ana, Mucavac, Lucija, Matić, Toni, Bekić, Sara Dejanović, Konja, Josip, Rajić, Ljubica
Format: Article
Language:English
Subjects:
Abstracts
Anaplastic large-cell lymphoma
Brain tumors
Children
Epidemiology
Hematology
Hodgkin's lymphoma
Lymphocytes B
Lymphocytes T
Lymphoma
Pediatrics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lymphomas are the third most common malignant disease in childhood, after leukemia and brain tumors. The aim of this study is to show stratification by gender and age as well as long term survival in pediatric patients diagnosed with Non-Hodgkin Lymphoma in our center.Our retrospective analysis included 85 children with newly diagnosed NHL from January 1, 1997 to December 31, 2016. They all have been diagnosed and treated at the Department of Pediatric Hematology and oncology, University Hospital Centre Zagreb.Out of 85 children with newly diagnosed NHL 48 of them suffered from B-cell NHL (n = 48; 56%) while the rest of them had T-cell lymphoblastic lymphoma(T-LBL) (n = 20; 24%) or Anaplastic large-cell lymphoma (ALCL) (n = 17; 20%). There were 25 girls and 50 boys (age 3 – 17 years). Overall survival (OS) for the entire group was 78.82%. Diagnose based survival is in the favor of T-LBL – 85.00% in comparison to 81.25% in B-NHL and 64.71% in ALCL.Our survival rates are not very different from the ones in the other European countries. We expect improved survival rates after introducing novel treatment that would optimize therapeutic effect and at the same time minimize the risk of severe late toxic effects.
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2021-europaediatrics.295